GSDMD inhibitor and application thereof in prevention and treatment of atherosclerosis and sepsis
A technology for atherosclerosis and sepsis, applied in the field of biomedicine, to prevent and treat atherosclerosis and sepsis, reduce pyroptosis, and inhibit pyroptosis
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0050] Prevention and treatment effect of GSDMD polypeptide inhibitor on atherosclerosis:
[0051] 1. The 5-week-old ApoE- / - mice were fed with high-fat diet (21% fat, 0.15% cholesterol), and samples were taken at 6, 8, 11, 14, and 18 weeks of age, and the Western Blot method was used to detect blood vessels. The activation levels of Caspase-1 and GSDMD; it was found that with the progression of atherosclerosis, the activation levels of Caspase-1 and GSDMD in vascular tissue increased significantly (see attached image 3 ), suggesting that the activation level of Caspase-1 / GSDMD pathway may play an important role in the process of atherosclerosis.
[0052] 2. After 5 weeks old ApoE- / - mice were fed with high-fat diet for 9 weeks, the control group was given control solvent; the Caspase-1 inhibitor group was given Z-YVAD-FMK (Caspase-1 inhibitor, intraperitoneal injection , 200 μg / day); GSDMD inhibitor group received Z-LLSD-FMK (GSDMD inhibitor, intraperitoneal injection, 200 ...
Embodiment 2
[0055] Prevention and treatment effect of GSDMD polypeptide inhibitor on sepsis:
[0056] Using 10-week-old C57 mice, the control group was given a control solvent; the Caspase-1 inhibitor group was given Z-YVAD-FMK (caspase-1 inhibitor, intraperitoneal injection, 200 μg / day); the GSDMD inhibitor group was given Z -LLSD-FMK (GSDMD inhibitor, intraperitoneal injection, 200 μg / day) or Caspase-1 inhibitor plus GSDMD inhibitor group with Z-YVAD-FMK+Z-LLSD-FMK (intraperitoneal injection, each 200 μg / day) Intervention for 5 days, intraperitoneal injection of LPS (20mg / kg) at the same time on the 5th day; the results found that compared with the control group, Caspase-1 inhibitor group, GSDMD inhibitor group and Caspase-1 inhibitor + GSDMD inhibitor Both groups significantly improved the survival rate of mice, decreased plasma LDH and HMGB1 levels, and there was no significant difference among the inhibitor groups (such as Figure 7 ). At the same time, the activation level of Casp...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com